Resoundant’s Magnetic Resonance Elastography Accepted into FDA Biomarker Qualification Program as a Reasonably Likely Surrogate Endpoint in MASH Trials
Rochester, MN — December 16, 2025 — Resoundant, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Letter of Intent into the FDA’s Biomarker Qualification Program (BQP) for Liver Stiffness Measurement (LSM) by Magnetic Resonance Elastography (MRE) as a Reasonably Likely Surrogate Endpoint (RLSE) in clinical trials for adults with noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced fibros
Dec 162 min read
Evaluating Diagnostic Accuracy and Cost Implications in MASLD Fibrosis Staging
As noninvasive tests (NITs) continue to replace liver biopsy in MASLD clinical practice and trials, the performance characteristics of...
Apr 282 min read
Resoundant Appoints Kay Pepin, PhD, as Chief Operating Officer
Rochester, MN – July 30, 2024 – Resoundant, Inc., a leader in the development and implementation of advanced magnetic resonance...
Jul 31, 20243 min read
Resoundant Applauds FDA Approval of Resmetirom: A Milestone for MASLD and MASH Patients
Rochester, MN – Resoundant, a Mayo Clinic company and the developer of Magnetic Resonance Elastography (MRE), is thrilled to announce the...
Mar 15, 20243 min read
Study: Utility and impact of magnetic resonance elastography in the clinical course and management of chronic liver disease
Colin Feuille, Swathi Kari, Roshan Patel, Rohan Oberoi, Jonathan Liu, Michael Ohliger, Mandana Khalili & Michele Tana Scientific Reports...
Jan 22, 20247 min read